Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
CEPI and GSK announce collaboration to strengthen the global effort to develop a vaccine for the 2019-nCoV virus
GSK to make adjuvant technology available to support rapid development of candidate vaccines
Read more -
GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development
GSK announced that it has licensed its M72/AS01E3 tuberculosis disease (TB) vaccine.
Read more -
US Food and Drug Administration (FDA) grants priority review of belantamab mafodotin for patients with relapsed or refractory multiple myeloma
Belantamab mafodotin has potential to be the first anti-BCMA treatment available to patients
Read more -
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir, an investigational, first-in-class attachment inhibitor for the treatment of HIV in adults with few treatment options available
ViiV Healthcare submits regulatory application to the European Medicines Agency for fostemsavir.
Read more -
Deborah Waterhouse, CEO of ViiV Healthcare, to join GSK Corporate Executive Team (CET)
GlaxoSmithKline plc today announced that Deborah Waterhouse, CEO of ViiV Healthcare, will join GSK’s Corporate Executive Team
Read more -
ViiV Healthcare receives complete response letter from US FDA for use of investigational cabotegravir and rilpivirine long-acting regimen in the treatment of HIV
ViiV Healthcare received a CRL from the FDA regarding its application for cabotegravir and rilpivirine.
Read more -
GSK announces positive headline results in phase 3 study of Benlysta in patients with lupus nephritis
BLISS-LN achieves primary endpoint and all major secondary endpoints. On-track for regulatory submission during the first half of 2020.
Read more -
Pivotal DREAMM-2 study demonstrated a clinically meaningful overall response rate with belantamab mafodotin (GSK2857916) for patients with relapsed/refractory multiple myeloma
GSK announced treatment with the investigational single-agent belantamab mafodotin
Read more -
ViiV Healthcare files submissions to the FDA and EMA for the first-ever dispersible formulation of dolutegravir (DTG) for children living with HIV
If approved, this new formulation of DTG will be the first integrase inhibitor available as a dispersible tablet for children living with HIV - closing the gap between treatment...
Read more -
GSK employees celebrate #GivingTuesday with $190,000 in awards to local nonprofits
GSK announced on #GivingTuesday that its employees have selected 19 local nonprofit organizations to each receive $10,000 charitable gifts to support their work making communiti...
Read more -
GSK awarding $400,000 to Greater Philadelphia nonprofits making an IMPACT on health outcomes
GSK today honored 10 local nonprofits that offer youth mentoring, housing, legal aid, education and other critical services that help foster a healthier Philadelphia region.
Read more -
GSK awards Triangle nonprofits making a powerful IMPACT on health outcomes
Ten North Carolina nonprofits will each receive $40,000 to support Housing, Skills Training, Food Access and other social determinants of health
Read more -
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*)
GSK delivers sales of £9.4 billion +16% AER, +11% CER (Pro-forma +6% CER*) Total EPS 31.4p +9% AER, -1% CER; Adjusted EPS 38.6p +9% AER, +1% CER
Read more -
GSK starts a phase III clinical programme for a potential first-in-class antibiotic, gepotidacin
First in a new chemical class of antibiotic with a mechanism of action distinct from any currently approved antibiotic. Investigating use for uncomplicated urinary tract infect...
Read more -
GSK receives prestigious Prix Galien USA award for SHINGRIX
SHINGRIX recognized as 2019 Best Pharmaceutical Product, following Galien Award win in Germany last week, acknowledging the health impact of innovative vaccine
Read more -
GSK announces new events in the "Us in Lupus" campaign to reach women of color
The initiative is designed to complement the virtual Us in Lupus program, a 12-week online education program and community for people newly diagnosed with lupus.
Read more -
GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
GSK Announces U.S. Food and Drug Administration Approval of Additional Indication for Zejula (niraparib) for Late-line Treatment for Women with Recurrent Ovarian Cancer
Read more -
GSK agrees to divest rabies and tick-borne encephalitis vaccines to Bavarian Nordic
GSK to receive upfront payment of approximately EUR301 million (£259m) and milestone payments for a total consideration of up to EUR955 million (£822m)
Read more -
GSK and Lyell Immunopharma join forces to develop the next generation of cancer cell therapies
Collaboration will combine Lyell’s technologies with GSK’s pipeline of cell therapies and manufacturing capability
Read more -
GSK submits filing to FDA for Trelegy Ellipta use in patients with asthma
GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) today announced the filing of a supplemental New Drug Application (sNDA) to the US Food and Drug Administration (FDA) seeking...
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We make a wide range of prescription medicines, vaccines and consumer healthcare products.
-
Research
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines
